Unité Molécules de Communication et Adaptation des Microorganismes (MCAM), Muséum National d'Histoire Naturelle, CNRS, Paris, France.
UMR_MD1, Inserm U-1261, Faculté de Pharmacie, Université Aix-Marseille, Marseille, France.
Infect Immun. 2019 Oct 18;87(11). doi: 10.1128/IAI.00556-19. Print 2019 Nov.
The level of human group IIA secreted phospholipase A (hGIIA sPLA) is increased in the plasma of malaria patients, but its role is unknown. In parasite culture with normal plasma, hGIIA is inactive against , contrasting with hGIIF, hGV, and hGX sPLAs, which readily hydrolyze plasma lipoproteins, release nonesterified fatty acids (NEFAs), and inhibit parasite growth. Here, we revisited the anti- activity of hGIIA under conditions closer to those of malaria physiopathology where lipoproteins are oxidized. In parasite culture containing oxidized lipoproteins, hGIIA sPLA was inhibitory, with a 50% inhibitory concentration value of 150.0 ± 40.8 nM, in accordance with its capacity to release NEFAs from oxidized particles. With oxidized lipoproteins, hGIIF, hGV, and hGX sPLAs were also more potent, by 4.6-, 2.1-, and 1.9-fold, respectively. Using specific immunoassays, we found that hGIIA sPLA is increased in plasma from 41 patients with malaria over levels for healthy donors (median [interquartile range], 1.6 [0.7 to 3.4] nM versus 0.0 [0.0 to 0.1] nM, respectively; < 0.0001). Other sPLAs were not detected. Malaria plasma, but not normal plasma, contains oxidized lipoproteins and was inhibitory to when spiked with hGIIA sPLA Injection of recombinant hGIIA into mice infected with reduced the peak of parasitemia, and this was effective only when the level of plasma peroxidation was increased during infection. In conclusion, we propose that malaria-induced oxidation of lipoproteins converts these into a preferential substrate for hGIIA sPLA, promoting its parasite-killing effect. This mechanism may contribute to host defense against in malaria where high levels of hGIIA are observed.
人 IIA 组分泌型磷脂酶 A(hGIIA sPLA)在疟疾患者的血浆中水平升高,但作用尚不清楚。在正常血浆的寄生虫培养中,hGIIA 对 无活性,与 hGIIF、hGV 和 hGX sPLAs 形成对比,后三者可轻易水解血浆脂蛋白,释放非酯化脂肪酸(NEFAs)并抑制寄生虫生长。在这里,我们在更接近疟疾病理生理学条件下重新研究了 hGIIA 的抗 活性,即在脂蛋白氧化的条件下。在含有氧化脂蛋白的寄生虫培养中,hGIIA sPLA 具有抑制作用,其 50%抑制浓度值为 150.0±40.8 nM,这与它从氧化颗粒中释放 NEFAs 的能力一致。使用特异性免疫测定法,我们发现 hGIIF、hGV 和 hGX sPLAs 的效力也分别提高了 4.6、2.1 和 1.9 倍。通过使用特异性免疫测定法,我们发现,与健康供体相比,来自 41 名疟疾患者的血浆中 hGIIA sPLA 的水平升高(中位数[四分位数范围],1.6[0.7 至 3.4]nM 对 0.0[0.0 至 0.1]nM; < 0.0001)。未检测到其他 sPLAs。疟疾血浆,但不是正常血浆,含有氧化脂蛋白,当用 hGIIA sPLA 处理时会抑制 。当在感染期间增加血浆过氧化物水平时,向感染 的小鼠注射重组 hGIIA 可降低寄生虫血症的峰值,而且这种作用是有效的。总之,我们提出,脂蛋白在疟疾诱导的氧化作用下转化为 hGIIA sPLA 的优先底物,从而增强其杀寄生虫作用。这种机制可能有助于宿主防御疟疾中观察到的高水平 hGIIA 的寄生虫感染。